Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Natural compound library screening identifies new molecules for the treatment of cardiac fibrosis and diastolic dysfunction

[img]
Preview
PDF (Original Manuskript (Final Draft)) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
28MB
[img]
Preview
PDF (Supplementary Materials) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
9MB

Item Type:Article
Title:Natural compound library screening identifies new molecules for the treatment of cardiac fibrosis and diastolic dysfunction
Creators Name:Schimmel, K. and Jung, M. and Foinquinos, A. and San José, G. and Beaumont, J. and Bock, K. and Grote-Levi, L. and Xiao, K. and Bär, C. and Pfanne, A. and Just, A. and Zimmer, K. and Ngoy, S. and López, B. and Ravassa, S. and Samolovac, S. and Janssen-Peters, H. and Remke, J. and Scherf, K. and Dangwal, S. and Piccoli, M.T. and Kleemiss, F. and Kreutzer, F.P. and Kenneweg, F. and Leonardy, J. and Hobuß, L. and Santer, L. and Do, Q.T. and Geffers, R. and Braesen, J.H. and Schmitz, J. and Brandenberger, C. and Müller, D.N. and Wilck, N. and Kaever, V. and Bähre, H. and Batkai, S. and Fiedler, J. and Alexander, K.M. and Wertheim, B.M. and Fisch, S. and Liao, R. and Diez, J. and González, A. and Thum, T.
Abstract:BACKGROUND: Myocardial fibrosis is a hallmark of cardiac remodeling and functionally involved in heart failure (HF) development, a leading cause of deaths worldwide. Clinically there is no therapeutic strategy available that specifically attenuates maladaptive responses of cardiac fibroblasts, the effector cells of fibrosis in the heart. Therefore, we aimed at the development of novel anti-fibrotic therapeutics based on natural-derived substance library screens for the treatment of cardiac fibrosis. METHODS: Anti-fibrotic drug candidates were identified by functional screening of 480 chemically diverse natural compounds in primary human cardiac fibroblasts (HCFs), subsequent validation and mechanistic in vitro and in vivo studies. Hits were analyzed for dose-dependent inhibition of proliferation of HCFs, for modulation of apoptosis and extracellular matrix expression. In vitro findings were confirmed in vivo, using an angiotensin II (Ang II)-mediated murine model of cardiac fibrosis in both preventive and therapeutic settings, as well as in the Dahl salt sensitive rat model. To investigate the mechanism underlying the anti-fibrotic potential of the lead compounds, treatment-dependent changes in the noncoding RNAome in primary HCFs were analyzed by RNA-deep sequencing. RESULTS: High-throughput natural compound library screening identified 15 substances with antiproliferative effects in HCFs. Using multiple in vitro fibrosis assays and stringent selection algorithms we identified the steroid bufalin (from Chinese toad venom) and the alkaloid lycorine (from Amaryllidaceae species) to be effective anti-fibrotic molecules both in vitro and in vivo leading to improvement in diastolic function in two hypertension-dependent rodent models of cardiac fibrosis. Administration at effective doses did not change plasma damage markers nor the morphology of kidney and liver, providing first toxicological safety data. By next-generation sequencing we identified the conserved microRNA (miR) miR-671-5p and downstream the antifibrotic selenoprotein P1 (SEPP1) as common effectors of the anti-fibrotic compounds. CONCLUSION: We identified the molecules bufalin and lycorine as drug candidates for therapeutic applications in cardiac fibrosis and diastolic dysfunction.
Keywords:Diastolic Dysfunction, Cardiac Fibrosis, Hypertension, Bufalin, Lycorine, miR-671-5p, Animals, Mice, Rats
Source:Circulation
ISSN:0009-7322
Publisher:American Heart Association (U.S.A.)
Date:17 January 2020
Official Publication:https://doi.org/10.1161/CIRCULATIONAHA.119.042559
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library